KR101575722B1 - Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect - Google Patents

Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect Download PDF

Info

Publication number
KR101575722B1
KR101575722B1 KR1020130128604A KR20130128604A KR101575722B1 KR 101575722 B1 KR101575722 B1 KR 101575722B1 KR 1020130128604 A KR1020130128604 A KR 1020130128604A KR 20130128604 A KR20130128604 A KR 20130128604A KR 101575722 B1 KR101575722 B1 KR 101575722B1
Authority
KR
South Korea
Prior art keywords
extract
corn oil
composition
delete delete
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020130128604A
Other languages
Korean (ko)
Other versions
KR20150048478A (en
Inventor
서주원
이지언
이동령
Original Assignee
명지대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 명지대학교 산학협력단 filed Critical 명지대학교 산학협력단
Priority to KR1020130128604A priority Critical patent/KR101575722B1/en
Publication of KR20150048478A publication Critical patent/KR20150048478A/en
Application granted granted Critical
Publication of KR101575722B1 publication Critical patent/KR101575722B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/40Cornaceae (Dogwood family)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/02Antioxidant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/13Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/17Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 산수유 추출물을 함유하는 항산화, 항균 또는 항염 조성물에 관한 것이다.
상기와 같은 본 발명에 따르면, 산수유 추출물을 유효성분으로 함유하는 항산화, 항균 및 항염 효과가 우수한 조성물을 피부 외용제 조성물로 이용함으로써, 여드름, 아토피, 무좀, 건선, 습진 또는 피부염 등과 같은 피부질환을 개선하는 효과가 있다.
The present invention relates to an antioxidant, antibacterial or anti-inflammatory composition containing a corn oil extract.
According to the present invention as described above, it is possible to improve the skin diseases such as acne, atopy, athlete's foot, psoriasis, eczema or dermatitis by using a composition having an antioxidant, antibacterial and anti-inflammatory effect, .

Description

산수유 추출물을 함유하는 항산화, 항균, 항염 조성물{COMPOSITION COMPRISING THE CORNUS OFFICINALIS EXTRACT FOR ANTI-OXIDANT, ANTI-BACTERIAL, ANTI-INFLAMMATORY EFFECT}FIELD OF THE INVENTION [0001] The present invention relates to antioxidant, antimicrobial and anti-inflammatory compositions containing an extract of corn oil,

본 발명은 산수유 추출물을 함유하는 항산화, 항균 또는 항염 조성물에 관한 것이다.The present invention relates to an antioxidant, antibacterial or anti-inflammatory composition containing a corn oil extract.

여드름은 모든 연령대에서 대부분의 사람들에게 발생하며, 면포 또는 농포 등을 형성하는 피부질환이다. 여드름의 발생원인은 과도한 피지분비, 호르몬 불균형, 모낭 내 이상 각화 및 Propionibacterium acnes의 증식 및 염증반응 등의 복합적인 요인으로 발생한다. 여드름 원인균인 P. acnes는 혐기성 피부 상재균으로 모낭 내에서 증식하며, 피지의 트리글리세라이드를 리파아제가 가수분해하여 생성되는 유리지방산과 이에 의한 모낭의 자극으로 화학주성인자(chemotactic factor)가 발생하여 염증반응을 일으킨다. P. acnes 감염에 의한 여드름의 치료방법은 항생제 투여가 가장 많이 사용되고 있으나, 항생제의 내성 등에 의해 치료 효과가 떨어질 수 있다. 이에, 여드름 치료에 생약 유래 물질에 대한 연구가 활발히 진행되고 있다. Acne occurs in most people of all ages and is a skin disease that forms jaundice or pustule. The cause of acne is caused by complex factors such as excessive sebum secretion, hormone imbalance, abnormal keratinization in hair follicle, proliferation of Propionibacterium acnes and inflammatory reaction. P. acnes , a causative agent of acne, is an anaerobic skin fungus that proliferates in the hair follicle, and triglycerides of sebum are produced by free radicals produced by hydrolysis of lipase, and by the stimulation of the hair follicles by the chemotactic factor, Reaction. The treatment of acne caused by P. acnes infection is most commonly used with antibiotics, but its effectiveness may be deteriorated due to resistance to antibiotics. Therefore, studies on herbal medicine-derived substances for the treatment of acne have been actively conducted.

최근 여러 가지 화학물질 등에 의한 피부자극을 줄이기 위해 천연물을 사용한 화장품이 다양하게 개발되고 있으며. 천연재료는 피부에 부작용이 적을 뿐만 아니라 소비자들의 호응이 높아 화장품 원료로써 개발가치가 증가하고 있는 추세이다.Recently, various cosmetic products using natural products have been developed to reduce skin irritation caused by various chemicals. Natural materials are not only less harmful to the skin but also have a high level of consumer value, which is a development value as a raw material for cosmetics.

대한민국 등록특허 제10-1253374호(여드름 피부 개선용 화장료 조성물)는 여드름 피부 개선을 위한 화장료 조성물로 김치유산균발효추출물과 대두발효추출물을 이용하고, 대한민국 등록특허 제10-0879032호(천연 항균 및 항염 효과가 있는 항균, 항산화 및 항염억제제 및 이를 함유하는 화장료 조성물)는 한약재 감초, 지모, 독활, 황백, 황련, 고삼, 황금, 괴화, 자초 혼합 추출물을 이용하여, 항균 효과가 있는 화장료 조성물을 제공하고 있다.Korean Patent No. 10-1253374 (Cosmetic composition for improving acne skin) is a cosmetic composition for improving acne skin using fermented extract of Kimchi lactic acid bacteria and fermented soybean extract, and Korean Patent No. 10-0879032 (natural antibacterial and anti-inflammatory Antimicrobial, antioxidant and antiinflammatory agents having an effect and a cosmetic composition containing the same) provide a cosmetic composition having antimicrobial effect by using the herbal medicine licorice, zymo, chewyum, yellow whites, have.

산수유는 층층나무과(Comaceae)에 속하는 약용식물로서 그 열매는 길이 1.5 cm 내외의 중추원형 모양이며, 신맛이 두드러져 촉산초라고도 불리고 자양강장 효과를 가진 천연식품으로 널리 이용되고 있다. 산수유에는 결정성 유기산, 몰식자산, 사과산, 포도주산 등이 있으며, 모르로니시드, 로가닌 등 이리도이드 배당체가 알려져 있다. 한방자료 기록에 의하면 산수유는 그 맛이 시고 성질이 따뜻하며, 당뇨증, 요통, 이명, 폐결핵 등의 치료제로 사용되어 왔고, 이뇨작용, 혈압강하작용, 항암 등의 약리작용이 있다고 알려져 있다. It is a medicinal plant belonging to the Comaceae family. Its fruit is a circular shape with a length of about 1.5 cm. It is widely used as a natural food having a natural tonic effect. Mountainous oils include crystalline organic acids, gallic acid, malic acid, and wine acids, and iridoid glycosides such as moronic acid and roganin are known. According to the records of oriental medicine, it is known that corn oil is tasteful and warm in nature, and has been used as a treatment for diabetes, back pain, tinnitus, pulmonary tuberculosis and the like, and has pharmacological actions such as diuretic action, hypotensive action, and anticancer.

그러나, 산수유를 화장료 조성물이나 피부 외용제 조성물의 소재로 적용한 예는 많지 않으며, 열매를 중심으로 그 효능이 연구되어 산수유 꽃에 대한 연구는 미흡한 실정이다. 산수유 꽃은 차로 음용이 가능하기 때문에 인체에 미치는 독성이 거의 없다. 또한, 선행기술은 산수유를 다른 천연소재와 혼합하여 혼합물의 효과만을 제시하고 있을 뿐, 산수유 자체의 효능을 이용하여 여드름, 아토피 등의 피부염에 적용한 예는 없다. However, there are not many examples of application of corn oil as a cosmetic composition or a composition for external application for skin, and the effect of the corn oil on the fruit has been studied. Corn flour is almost toxic to the human body because it can be drunk by car. Also, the prior art discloses only the effect of the mixture of corn syrup mixed with other natural materials, and there is no example applied to the dermatitis such as acne and atopy by utilizing the effect of corn syrup itself.

대한민국 등록특허 제10-0361040호(황백, 산수유, 대황, 행인, 당귀, 정향 및 띠 추출물을 안정화한 니오좀을 함유하는 화장료 조성물)는 황백, 산수유, 대황, 행인, 당귀, 정향 및 띠의 추출물을 니오좀에 효과적으로 안정화함으로써 피부 침투 효과를 증진시켜 피부 탄력 증진 및 지속적인 보습 효과를 제공한 것으로서, 선행기술은 산수유 열매를 다른 천연소재와 혼합하여 이용하고 있을 뿐이다. 이에, 본 발명자들은 산수유 추출물, 더 나아가 산수유 꽃 추출물의 새로운 용도를 제공하고자 한다. Korean Patent No. 10-0361040 (a cosmetic composition containing a niozyme stabilized with yellow rose, rhubarb, rhubarb, passerine, angelica, clove and band extract) is an extract of yellow, white, Is effectively stabilized in the nyoxis, thereby improving the penetration of the skin, thereby promoting skin elasticity and providing a continuous moisturizing effect. The prior art is merely using a mixture of natural fruit with corn oil. Accordingly, the present inventors intend to provide a new use of the corn oil extract, furthermore the corn oil flower extract.

본 발명의 목적은 부작용이 없는 천연물 소재인 산수유 추출물의 새로운 용도를 제공하여, 산수유 추출물을 유효성분으로 함유하는 항산화, 항균 및 항염 효과가 있는 조성물을 제공함에 있다.It is an object of the present invention to provide a novel use of a marine oil extract, which is a natural material without side effects, and to provide a composition having antioxidative, antibacterial and anti-inflammatory effects containing a marine oil extract as an effective ingredient.

상기 목적을 달성하기 위하여, 본 발명은 산수유(Cornus officinalis) 추출물을 유효성분으로 함유하는 항산화, 항균 또는 항염 조성물을 제공한다.In order to achieve the above object, the present invention provides an antioxidant, antibacterial or anti-inflammatory composition containing Cornus officinalis extract as an active ingredient.

상기 산수유 추출물은 산수유 꽃 추출물인 것을 특징으로 한다.Wherein the acidified milk extract is characterized in that it is a sour milk flower extract.

상기 산수유 추출물은 용매 추출법, 초임계 추출법 또는 초음파 추출법으로 추출된 것을 특징으로 한다.The mushroom oil extract is characterized by being extracted with a solvent extraction method, a supercritical extraction method, or an ultrasonic extraction method.

이때, 상기 용매 추출법은 물, 탄소수 1 내지 4의 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 디프로필렌글리콜, 글리세린, 아세톤, 에틸아세테이트, 클로로포름, 메틸렌클로라이드, 부틸아세테이트, 디에틸에테르, 디클로로메탄 및 헥산을 포함하는 군에서 선택되는 1 이상의 추출용매를 이용한 것을 특징으로 한다.At this time, the solvent extraction method is a method in which the solvent extraction is carried out using water, a lower alcohol having 1 to 4 carbon atoms, propylene glycol, butylene glycol, dipropylene glycol, glycerin, acetone, ethyl acetate, chloroform, methylene chloride, butyl acetate, diethyl ether, dichloromethane, And an extraction solvent selected from the group consisting of:

상기 산수유 추출물은 항산화, 항균 또는 항염 조성물에 대하여 1 내지 99 중량%로 함유된 것을 특징으로 한다.The extract of corn oil is characterized by containing 1 to 99% by weight of the antioxidant, antibacterial or anti-inflammatory composition.

또한, 본 발명은 상기 항산화, 항균 또는 항염 조성물을 함유하는 피부 외용제 조성물을 제공한다.The present invention also provides a composition for external application for skin containing the above antioxidant, antibacterial or anti-inflammatory composition.

상기 피부 외용제 조성물은 여드름, 아토피, 무좀, 건선, 습진 및 피부염을 포함하는 군에서 선택되는 어느 하나의 피부질환을 개선하는 것을 특징으로 한다.The composition for external application for skin is characterized by improving any one of skin diseases selected from the group including acne, atopy, athlete's foot, psoriasis, eczema and dermatitis.

상기 피부 외용제 조성물은 프로피오니박테리움 아크네스(Propionibacterium acnes) 또는 스타필로코커스 에피더미디스(Staphylococcus epidermidis) 균주의 생장을 억제하는 것을 특징으로 한다.The composition for external application for skin is characterized by inhibiting the growth of Propionibacterium acnes or Staphylococcus epidermidis .

상기 피부 외용제 조성물은 연고제, 용액, 크림, 유액, 화장수, 로션, 젤, 에센스, 파운데이션, 팩, 스틱, 입욕제 또는 비누의 제형으로 제조된 것을 특징으로 한다.The composition for external application for skin is characterized in that it is formulated into an ointment, solution, cream, emulsion, lotion, lotion, gel, essence, foundation, pack, stick, bath or soap.

또한, 본 발명은 상기 항산화, 항균 또는 항염 조성물을 함유하는 건강기능식품을 제공한다.The present invention also provides a health functional food containing the antioxidant, antibacterial or anti-inflammatory composition.

상기와 같은 본 발명에 따르면, 산수유 추출물을 유효성분으로 함유함으로써, 항산화, 항균 및 항염 효과가 우수한 조성물을 제공하여 여드름, 아토피, 무좀, 건선, 습진 또는 피부염 등과 같은 피부질환을 개선하는 효과가 있다.According to the present invention, by containing a corn oil extract as an active ingredient, it provides a composition having excellent antioxidative, antibacterial and anti-inflammatory effects and is effective for improving skin diseases such as acne, atopy, athlete's foot, psoriasis, eczema or dermatitis .

본 발명에 따른 산수유 추출물을 함유하는 조성물은 여드름 원인균인 프로피오니박테리움 아크네스(Propionibacterium acnes)뿐만 아니라, 여드름균 감염 이후 2차 피부 감염균인 스타필로코커스 에피더미디스(Staphylococcus epidermidis)에 대하여 항균 작용이 우수해 여드름 개선에 뛰어난 효과가 있고, 대식세포에서 염증 관련 사이토카인 TNF-α를 억제시킴과 동시에 LPS 자극 후 대식세포에서 분비되는 NO 생성을 억제하는 우수한 항염증 효과가 있다.The composition containing the extract of corn oil according to the present invention can be used not only for Propionibacterium acnes which is a cause of acne but also for Staphylococcus epidermidis which is a second skin infectious microorganism after acne infection, And excellent anti-inflammatory effect, which inhibits inflammation-related cytokine TNF-α in macrophages and suppresses NO production secreted by macrophages after LPS stimulation.

도 1은 산수유 추출물의 제조공정.
도 2는 산수유 추출물의 DPPH를 이용한 항산화 활성 결과.
도 3은 산수유 추출물의 TNF-α 억제 활성 결과.
도 4는 산수유 추출물의 NO(Nitric Oxide) 억제 활성 결과.
Fig. 1 shows a process for producing a corn oil extract.
Fig. 2 shows the results of antioxidant activity of DPPH extract of corn oil.
Fig. 3 shows the results of TNF-a inhibitory activity of the extract of Cornus syrup.
Fig. 4 shows the NO (nitric oxide) inhibitory activity of the extract of corn oil.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 산수유(Cornus officinalis) 추출물을 유효성분으로 함유하는 항산화, 항균 또는 항염 조성물을 제공한다.The present invention provides an antioxidant, antibacterial or anti-inflammatory composition containing Cornus officinalis extract as an active ingredient.

상기 산수유 추출물은 산수유 꽃 추출물인 것이 바람직하다.It is preferable that the above-mentioned crude oil extract is a flower oil extract.

상기 산수유 추출물은 용매 추출법, 초임계 추출법 또는 초음파 추출법으로 추출된 것이 바람직하며, 냉침추출, 열수추출, 환류냉각추출 또는 가열추출에 의해 추출될 수 있다. 용매 추출법은 물, 탄소수 1 내지 4의 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 디프로필렌글리콜, 글리세린, 아세톤, 에틸아세테이트, 클로로포름, 메틸렌클로라이드, 부틸아세테이트, 디에틸에테르, 디클로로메탄 및 헥산을 포함하는 군에서 선택되는 1 이상의 추출용매를 이용하는 것이 바람직하다.The crude oil extract may be extracted by a solvent extraction method, a supercritical extraction method or an ultrasonic extraction method, and may be extracted by cold extraction, hot water extraction, reflux cooling extraction or heat extraction. The solvent extraction method can be carried out in the presence of water, a lower alcohol having 1 to 4 carbon atoms, propylene glycol, butylene glycol, dipropylene glycol, glycerin, acetone, ethyl acetate, chloroform, methylene chloride, butyl acetate, diethyl ether, dichloromethane and hexane It is preferable to use at least one extraction solvent selected from the group

더욱 구체적으로, 본 발명에 따른 산수유 추출물은 (1) 산수유 열매, 꽃 또는 이들의 혼합원료를 세척 및 건조시키는 단계; (2) 상기 건조된 산수유 원료를 추출용매에 침지시켜 산수유 추출물을 제조하는 단계; 및 (3) 상기 제조된 산수유 추출물을 여과 및 농축시키는 단계;를 포함하여 제조될 수 있다.More specifically, the extract of corn oil according to the present invention comprises (1) washing and drying the corn oil, the flower or the mixed material thereof; (2) a step of immersing the dried crude fermented milk in an extraction solvent to prepare a fermented milk extract; And (3) filtering and concentrating the prepared ferulic acid extract.

상기 (1)단계에서 건조는 20 내지 60 ℃에서 1 내지 2일 동안 건조시키는 것이 바람직하다.In the step (1), drying is preferably performed at 20 to 60 ° C for 1 to 2 days.

상기 (2)단계에서 추출공정은 산수유 원료 무게의 10 내지 20 배, 바람직하게는 10 내지 15 배에 해당하는 물, 탄소수 1 내지 4의 무수 또는 함수 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 디프로필렌글리콜, 글리세린, 아세톤, 에틸아세테이트, 클로로포름, 메틸렌클로라이드, 부틸아세테이트, 디에틸에테르, 디클로로메탄, 헥산 또는 이들을 혼합한 추출용매를 가하여 5 내지 100 ℃, 바람직하게는 20 내지 100 ℃, 더욱 바람직하게는 50 내지 90 ℃의 온도에서 12 내지 36 시간 동안 추출하는 것이 최적의 효과를 나타낸다. 상기 추출공정은 1 내지 5회 반복하여 추출하는 것이 바람직하며, 상기 저급 알코올로 메탄올, 에탄올 또는 부탄올을 이용할 수 있다.In the step (2), the extraction step may be carried out at a temperature of 10 to 20 times, preferably 10 to 15 times the weight of the raw materials of the acidic or unsaturated fatty acids, water, an anhydride or hydrous lower alcohol having 1 to 4 carbon atoms, propylene glycol, The reaction is carried out at a temperature of 5 to 100 ° C, preferably 20 to 100 ° C, more preferably 20 to 100 ° C, in the presence of an alcohol, glycol, glycerin, acetone, ethyl acetate, chloroform, methylene chloride, butyl acetate, diethyl ether, dichloromethane, Extraction at a temperature of 50 to 90 占 폚 for 12 to 36 hours shows the optimum effect. The extraction process is preferably repeated one to five times, and methanol, ethanol or butanol may be used as the lower alcohol.

상기 산수유 추출물은 항산화, 항균 또는 항염 조성물에 대하여 1 내지 99 중량%, 바람직하게는 20 내지 40 중량%로 함유된 것이 최적의 효과를 나타낸다.The extract of corn oil is contained in an amount of 1 to 99% by weight, preferably 20 to 40% by weight, based on the antioxidant, antibacterial or anti-inflammatory composition.

또한, 본 발명은 상기 항산화, 항균 또는 항염 조성물을 함유하는 피부 외용제 조성물을 제공한다.The present invention also provides a composition for external application for skin containing the above antioxidant, antibacterial or anti-inflammatory composition.

상기 피부 외용제 조성물은 피부 개선용 화장료 조성물로 이용될 수 있고, 여드름, 아토피, 무좀, 건선, 습진 및 피부염을 포함하는 군에서 선택되는 어느 하나의 피부질환을 개선하며, 피부의 노화, 주름 또는 탄력 소실을 예방하는 효과가 있다.The composition for external application for skin may be used as a cosmetic composition for improving skin and may be used for improving skin diseases selected from the group including acne, atopy, athlete's foot, psoriasis, eczema and dermatitis, There is an effect of preventing loss.

상기 피부 외용제 조성물은 프로피오니박테리움 아크네스(Propionibacterium acnes) 또는 스타필로코커스 에피더미디스(Staphylococcus epidermidis) 균주의 생장을 억제하는 효과가 있다.The composition for external application for skin has an effect of inhibiting the growth of Propionibacterium acnes or Staphylococcus epidermidis .

본 발명은 산수유 꽃에서 추출한 추출물이 여드름 원인균인 프로피오니박테리움 아크네스(Propionibacterium acnes)뿐만 아니라, 여드름균 감염 이후 2차 피부 감염균인 스타필로코커스 에피더미디스(Staphylococcus epidermidis)에 대하여 항균 작용이 우수해 여드름 개선에 뛰어난 효과가 있고, 대식세포에서 염증 관련 사이토카인 TNF-α를 억제시킴과 동시에 LPS 자극 후 대식세포에서 분비되는 NO 생성을 억제하는 우수한 항염증 효과가 있음을 제공한다. 테트라사이클린과 같은 항생제는 부작용 및 내성균의 출현 등 사용상의 한계점이 있는 반면, 본 발명에 따른 산수유 꽃 추출물은 안전하고 부작용이 없어 피부 외용제 조성물로 적합하다.The present invention is based on the finding that the extract extracted from corn oil flowers has excellent antimicrobial activity against Staphylococcus epidermidis which is a secondary skin infectious bacterium after acne fungus infection as well as Propionibacterium acnes which is an acne cause bacteria It has an excellent anti-acne effect, and it has excellent anti-inflammatory effect which inhibits inflammation-related cytokine TNF-α in macrophages and suppresses secretion of NO secreted by macrophages after LPS stimulation. Antibiotics such as tetracycline have limitations in use such as side effects and the appearance of resistant bacteria, while the extract of Sanskrit flowers according to the present invention is safe and has no side effects and is suitable as a composition for external application for skin.

상기 피부 외용제 조성물은 연고제, 용액, 크림, 유액, 화장수, 로션, 젤, 에센스, 파운데이션, 팩, 스틱, 입욕제 또는 비누의 제형으로 제조될 수 있다.The composition for external application for skin may be formulated into an ointment, solution, cream, emulsion, lotion, lotion, gel, essence, foundation, pack, stick, bath or soap.

또한, 본 발명은 상기 항산화, 항균 또는 항염 조성물을 함유하는 건강기능식품을 제공한다.The present invention also provides a health functional food containing the antioxidant, antibacterial or anti-inflammatory composition.

하기에 본 발명의 산수유 꽃 추출물을 포함하는 여러 가지 제형예를 설명하고 있으나, 이는 본 발명을 제한하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Various formulation examples including the extract of corn oil of the present invention are described below, but the present invention is not intended to be limited but is to be specifically described.

제형예 1. 유연 화장수(스킨 로션)Formulation Example 1. Flexible lotion (skin lotion)

실시예의 산수유 꽃 추출물.......5.0Corn oil extract of the example of the present invention ..... 5.0

글리세린...............................3.5Glycerin ............................... 3.5

올레일알코올......................1.5Oleyl alcohol ...................... 1.5

에탄올...................................5.5Ethanol ................................... 5.5

폴리솔베이트 80..................3.2Polysorbate 80 ............... 3.2

카르복실비닐폴리머............1.0Carboxyl vinyl polymer ............ 1.0

부틸렌 글리콜......................2.0Butylene glycol ...................... 2.0

프로필렌 글리콜..................2.0Propylene glycol .................. 2.0

방부제, 향료........................적량Preservative, fragrance ........................

정제수...................................잔량Purified water ................................... Remainder

계..............................................100Total .............................................. 100

상기의 조성에 따라 통상적인 방법으로 유연 화장수를 제조하였다(단위 중량%).Flexible lotion was prepared according to the above composition in a conventional manner (unit weight%).

제형예 2. 영양 화장수(밀크 로션)Formulation Example 2. Nourishing lotion (milk lotion)

실시예의 산수유 꽃 추출물........................5.0Corn oil extract of the example of the present invention 5.0

글리세린................................................3.0Glycerin ................................................ 3.0

부틸렌글리콜.........................................3.0Butylene glycol .......................................... 3.0

프로필렌글리콜......................................3.0Propylene glycol ...................................... 3.0

카르복시비닐폴리머..............................0.1Carboxyvinyl polymer 0.1

밀납...........................................................4.0Wax ................................................. 4.0 ... 4.0

폴리솔베이트 60......................................1.5Polysorbate 60 ...................................... 1.5

카프릴릭/카프릭 리글리세라이드........5.0Caprylic / Capriculiglyceride ........ 5.0

스쿠알란....................................................5.0Squalane ................................................. ... 5.0

솔비타세스퀴올레이트..............................1.5Solvatescequioleate .............................. 1.5

세테아릴 알코올.........................................1.0Cetearyl Alcohol ......................................... 1.0

트리에탄올아민............................................0.2Triethanolamine ............................................ 0.2

방부제, 향료...............................................적량Preservatives, fragrances ............................................... Suitable amount

정제수..........................................................잔량Purified water................................................. ......... Remaining

계....................................................................100system................................................. ................... 100

상기의 조성에 따라 통상적인 방법으로 영양 화장수를 제조하였다(단위 중량%).Nutrition lotion was prepared according to the above composition in a conventional manner (unit weight%).

제형예 3. 영양 크림Formulation Example 3. Nourishing cream

실시예의 산수유 꽃 추출물...........................3.0Corn oil extract of the example of the present invention 3.0

글리세린..................................................3.5glycerin................................................. .3.5

부틸렌글리콜...........................................3.0Butylene glycol ...............................................

유동파라핀...............................................7.0Liquid paraffin ...............................................

베타글루칸................................................7.0Beta Glucan ................................................ 7.0

카보머.........................................................0.1Cabomas ................................................ ......... 0.1

카프릴릭/카프릭 리글리세라이드.........3.0Caprylic / Capriculiglyceride ......... 3.0

스쿠알란.....................................................5.0Squalane ................................................. .... 5.0

세테아릴 글루코사이드............................1.5Cetearyl Glucoside ........................... 1.5

소르비탄 스테아레이트...........................0.4Sorbitan stearate ........................... 0.4

폴리솔베이트 60.........................................1.2Polysorbate 60 ......................................... 1.2

트리에탄올아민...........................................0.1Triethanolamine ........................................... 0.1

방부제, 향료.................................................적량Preservatives, fragrances ............................................... .. Good

정제수............................................................잔량Purified water................................................. ............ Remaining amount

계.....................................................................100system................................................. .................... 100

상기의 조성에 따라 통상적인 방법으로 영양 크림을 제조하였다(단위 중량%).Nutritive creams were prepared according to the above composition in a conventional manner (unit weight%).

제형예 4. 팩Formulation Example 4. Pack

실시예의 산수유 꽃 추출물.............8.0The extract of corn oil of the Example 8.0 ... 8.0

글리세린.....................................4.0Glycerin ..................................... 4.0

폴리비닐알콜............................15.0Polyvinyl alcohol ........................... 15.0

히알루론산 추출물...................5.0Hyaluronic Acid Extract 5.0

베타글루칸.................................7.0Beta Glucan ................................. 7.0

알란토인.......................................0.1Allantoin ....................................... 0.1

노닐 페닐에테르.........................0.4Nonyl phenyl ether ......................... 0.4

폴리솔베이트 60........................1.2Polysorbate 60 ............... 1.2

방부제, 향료..............................적량Preservative, fragrance ..............................

정제수.........................................잔량Purified water ......................................... Remaining amount

계....................................................100system................................................. ... 100

상기의 조성에 따라 통상적인 방법으로 팩을 제조하였다(단위 중량%).A pack was prepared according to the above composition in a conventional manner (unit weight%).

제형예 5. 국소 투여용 약제(패취제)Formulation Example 5. Pharmaceutical preparation for local administration (patch)

실시예의 산수유 꽃 추출물.......................................4.0The extract of corn oil of the example ....................................... 4.0

베타-1,3-글루칸..................................................3.0Beta-1,3-glucan ........................................... 3.0 3.0

디에틸아민.......................................................0.7Diethylamine ............................................... ........ 0.7

아황산나트륨.....................................................0.1Sodium Sulfite ................................................ ..... 0.1

폴리옥시에틸렌라우릴에테르(E.O=9)................................1.0Polyoxyethylene lauryl ether (EO = 9)

폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000)..........1.0Polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000) ......... 1.0

점성의 파라핀 오일...............................................2.5Viscous paraffin oil .............................................. .2.5

카프릴산에스테르/카프르산에스테르(Cetiol LC).....................2.5Caprylic acid ester / capric acid ester (Cetiol LC) 2.5

폴리에틸렌글리콜 400.............................................3.0Polyethylene glycol 400 ............................................... 3.0

폴리아크릴산(Carbopol 934P).......................................1.0Polyacrylic acid (Carbopol 934P) ....................................... 1.0

정제수...........................................................잔량Purified water................................................. .......... Remaining

계................................................................100system................................................. ............... 100

상기의 조성에 따라 통상적인 방법으로 국소 투여용 약제를 제조하였다(단위 중량%).According to the above composition, a medicament for topical administration was prepared by a conventional method (unit% by weight).

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

실시예 1. 산수유 추출물의 제조EXAMPLES Example 1. Preparation of Corn oil extract

산수유 꽃을 증류수로 1~2회 세척한 후 20 내지 60 ℃에서 1~2일간 건조시켜 추출원료를 준비하였다. The crude oil flowers were washed once or twice with distilled water, and then dried at 20 to 60 ° C for 1 to 2 days to prepare an extraction raw material.

준비한 산수유 꽃 50 g을 750 ml의 증류수, 메탄올 및 70 % 에탄올에 각각 침지시켜 50 내지 70 ℃에서 12 내지 36 시간 동안 추출하였다. 이후, 불용성 성분을 1~2배의 물로 세척하면서 5 ㎛ 이하의 공극 크기를 갖는 여과지로 자연여과한 다음, 당도 측정기로 측정하였을 때 약 3 내지 6 브릭스(Brix)가 될 때까지 감압 농축기로 농축하고 동결건조하여 습기가 없는 곳에서 믹서기로 균질화하였다(도 1).50 g of the prepared corn oil was dipped in 750 ml of distilled water, methanol and 70% ethanol, respectively, and extracted at 50 to 70 ° C for 12 to 36 hours. Thereafter, the insoluble component was washed with 1-2 times of water and naturally filtered with a filter paper having a pore size of 5 쨉 m or less, and then concentrated with a reduced pressure concentrator until a Brix of about 3 to 6 as measured by a sugar content meter Lyophilized and homogenized with a blender in the absence of moisture (Fig. 1).

상기 제조된 산수유 꽃 추출물 시료를 이용하여 하기와 같은 실험을 진행하였다.The following experiment was carried out using the prepared extract of Sanskrit flowers.

준비예. 실험균주 및 배양Preparation Yes. Experimental strain and culture

본 발명에 따른 실험예에서는 여드름 원인균인 프로피오니박테리움 아크네스(Propionibacterium acnes KCTC3314)와 그람 양성의 피부상재균인 스타필로코커스 에피더미디스(Staphylococcus epidermidis KTTC12228)를 이용하였다.In the experiment according to the present invention, Propionibacterium acnes KCTC3314, which is a causative agent of acne, and Staphylococcus epidermidis KTTC12228, which is a gram-positive skin preparation, were used.

P. acnes는 Reinforced clostridial(RC) 배지에 접종한 후 혐기성 배양조에서 Gaspack system을 이용하여 밀봉한 다음, 37 ℃에서 3 일 동안 혐기성 배양하였고, 호기성 균주인 S. epidermidis는 Mueller-Hinton 배지에 접종한 후 37 ℃에서 24 시간 동안 배양하여 사용하였다. P. acnes was inoculated into Reinforced clostridial (RC) medium, sealed in a gaspack system in an anaerobic incubator, anaerobically incubated at 37 ° C for 3 days, and aerobic strain S. epidermidis was inoculated on Mueller-Hinton medium And then cultured at 37 ° C for 24 hours.

실험예 1. 산수유 추출물의 항산화 활성Experimental Example 1. Antioxidant activity of the extract of corn oil

항산화 활성 측정은 DPPH(1,1-diphenyl-2-picryl hydrazyl)법을 이용하여 자유 라디칼(free radical) 소거능으로 측정하였으며 비교물질로 L-ascorbic acid를 사용하였다. DPPH와 양성대조군인 L-ascorbic acid는 시그마(Sigma)사의 것을 사용하였고, DPPH는 짙은 자색을 띄는 비교적 안정적인 자유 라디칼로서 시료에 의해 환원되어 탈색되므로 항산화 활성을 측정하는데 이용된다.Antioxidant activity was measured by free radical scavenging activity using DPPH (1,1-diphenyl-2-picryl hydrazyl) method and L-ascorbic acid was used as a comparative substance. DPPH and L-ascorbic acid (Sigma) were used as a positive control. DPPH was a stable, relatively stable free radical which was reduced by the sample and decolorized. Therefore, DPPH is used to measure antioxidative activity.

0.2 mM DPPH 에탄올 용액 200 ul에 2 배씩 연속적으로 희석(1000ug-0ug)시킨 추출물 시료를 실온에서 30 분간 반응시키고 517 nm에서 흡광도를 측정하였다. 하기 계산식을 사용하여 자유 라디칼 소거능을 구하였으며, 전자 공여능은 시료의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다. The extracts were continuously diluted (1000ug-0ug) twice in 200 μl of 0.2 mM DPPH ethanol solution and reacted at room temperature for 30 minutes. Absorbance was measured at 517 nm. The free radical scavenging activity was determined using the following equation, and the electron donating ability was represented by the absorbance reduction rate of the addition group of the sample and the no addition group.

자유 라디칼 소거능(%) = (1-시료첨가군의 흡광도/무첨가군의 흡광도) × 100Free radical scavenging ability (%) = (1-absorbance of sample addition group / absorbance of no addition group) x 100

자유 라디칼인 DPPH를 환원 또는 상쇄시키는 능력, 즉 산화를 억제하는 추출물 시료의 효과를 자유 라디칼 소거능으로 측정한 결과, 양성대조군인 L-ascorbic acid의 항산화 활성과 비교하여 보았을 때, 70 % EtOH 추출물의 경우에는 62.5 ug/ml 이상의 처리 농도까지 약 80 % 이상의 항산화 활성을 나타내었고, MeOH 추출물의 경우에는 31.25 ug/ml 이상의 처리 농도에서 약 85 % 이상의 항산화 활성 효과가 나타났다(도 2). 따라서, 산수유 추출물은 우수한 항산화 효과를 갖는 것을 확인하였다.The free radical scavenging ability of the extract inhibitor, ie, the ability to reduce or counteract the free radical DPPH, ie, oxidation inhibition, was evaluated by comparing the antioxidant activity of the positive control L-ascorbic acid with that of the 70% EtOH extract In the case of MeOH extract, the antioxidant activity was about 85% or more at a treatment concentration of 31.25 ug / ml or more (FIG. 2). Therefore, it was confirmed that the extract of corn oil has an excellent antioxidative effect.

실험예 2. 산수유 추출물의 항균 활성Experimental Example 2. Antimicrobial activity of the extract of corn oil

항균 활성 측정은 디스크 확산법(paper disk diffusion method)을 이용하였다.The antimicrobial activity was measured by the disk diffusion method.

여드름 원인균 P. acnes를 Reinforced clostridial(RC) 액체배지에서 3 일간 배양한 다음, 일정한 농도(optical density 620 nm에서 흡광도 0.5)로 조절된 균 현탁액을 멸균된 면봉을 이용하여 RC 한천플레이트(agar plate)에 균일하게 도말하였다. 이후, 플레이트를 건조시키고 paper disk(Φ 8mm, Adventec. USA)를 균주를 접종한 플레이트 표면 위에 올려놓고 추출물 시료를 농도별로 흡수시켰다. 시료가 처리된 플레이트를 혐기성 배양조에서 Gaspack system을 이용하여 3 일간 배양한 후 디스크 주위의 생육 억제환(inhibition zone) 크기로 항균 활성을 측정하였다. The acne causative organism P. acnes was cultured in a Reinforced clostridial (RC) liquid medium for 3 days, and then the suspension of the bacteria was adjusted to a constant concentration (optical density at 620 nm, absorbance 0.5) on an RC agar plate using a sterile cotton swab. . After that, the plate was dried and placed on a plate surface (Φ 8 mm, Adventec. USA) inoculated with the strain to absorb the extract sample by concentration. The plate treated with the sample was incubated in the anaerobic incubator for 3 days using the gaspack system, and the antimicrobial activity was measured in the inhibition zone size around the disk.

호기성 균주인 S. epidermidis에 대한 항균 활성 평가는 Muller-Hinton 배지를 사용하여 37 ℃에서 24 시간 동안 배양하는 것을 제외하고 상기 P. acnes와 동일한 방법으로 측정하였다.The antimicrobial activity evaluation against the aerobic strain S. epidermidis was carried out in the same manner as the above-mentioned P. acnes except that the antimicrobial activity was cultured at 37 DEG C for 24 hours using Muller-Hinton medium.

그 결과, 양성대조군인 테트라사이클린을 1 mg 처리하였을 때 억제환의 지름이 약 12 mm인 것으로 미루어 볼 때, 산수유 추출물은 P. acnes와 S. epidermidis 모두에 우수한 항균 효과가 있는 것을 알 수 있다. 테트라사이클린과 같은 항생제는 부작용 및 내성균의 출현 등 사용상의 한계점이 있는 반면, 본 발명에 따른 산수유 추출물은 안전하고 부작용이 없어 피부 외용제 조성물로 적합하다.As a result, when 1 mg of tetracycline as a positive control group was treated, the diameter of the inhibitory circle was about 12 mm. Thus, it can be seen that the extract of corn oil has excellent antimicrobial activity against both P. acnes and S. epidermidis. Antibiotics such as tetracycline have limitations in use such as side effects and appearance of resistant bacteria, while the extract of corn oil according to the present invention is safe and has no side effects and is suitable as a composition for external application for skin.

Figure 112013097532194-pat00001
Figure 112013097532194-pat00001

실험예 3. 산수유 추출물의 세포 독성EXPERIMENTAL EXAMPLE 3 Cytotoxicity of Cornicola oil Extract

우태아 혈청(FBS)이 없는 RPMI-1640 배지에서 배양하고 있는 인간 급성 단구성 백혈병세포 THP-1(Human acute monocytic leukemia)을 96 웰 마이크로 플레이트에 5×104 cells/well의 농도로 배양하였다. 추출물 시료를 농도별로 투여하여 24 시간 동안 배양한 후 상등액을 제거하고 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 측정방법에 따라 MTT 용액 100 ul를 36 ℃에서 4 시간 동안 처리하였다. 배양액을 제거하고 DMSO 50 ul를 처리한 후 흡광도 측정기(ELISA) 540 nm로 측정하여 측정값을 하기 식으로 계산하여 나타내었다.Human acute monocytic leukemia cells (THP-1) (human acute monocytic leukemia) cultured in RPMI-1640 medium without FBS were cultured in 96-well microplates at a concentration of 5 × 10 4 cells / well. The supernatant was removed and the supernatant was removed. 100 μl of the MTT solution was added to the solution in a solution of 36 Lt; 0 > C for 4 hours. After removing the culture medium and treating with 50 μl of DMSO, the absorbance was measured with an absorbance meter (ELISA) at 540 nm and the measured value was calculated by the following formula.

세포 독성(%) = (1-시료첨가군의 흡광도/무첨가군의 흡광도) × 100Cytotoxicity (%) = (1-absorbance of sample-added group / absorbance of no-added group) × 100

실험예 4. 산수유 추출물의 항염 활성 - TNF-α 억제Experimental Example 4. Anti-inflammatory activity of crude oil extract - TNF-α inhibition

우태아 혈청(FBS)이 없는 RPMI-1640 배지에서 배양하고 있는 인간 급성 단구성 백혈병세포 THP-1(Human acute monocytic leukemia)을 96 웰 마이크로 플레이트에 5×104 cells/well의 농도로 배양하였다. 추출물 시료를 농도별로 투여하여 24 시간 동안 배양한 후, FBS를 포함한 배지로 3 번 씻어 추출물 시료를 농도별로 처리하여 2 시간 동안 전 배양하였다. 이후, 지질다당류(Lipopolysaccharide, LPS)를 6 시간 동안 처리하고, 원심분리 후 상등액을 TNF-α ELISA Kit(BD 555212)에 분주하여 흡광도 측정기 ELISA reader로 450 ㎚에서 흡광도를 측정하였다.Human acute monocytic leukemia cells (THP-1) (human acute monocytic leukemia) cultured in RPMI-1640 medium without FBS were cultured in 96-well microplates at a concentration of 5 × 10 4 cells / well. The extracts were incubated for 24 hours, washed three times with FBS, and the extracts were pre - cultured for 2 hours. Lipopolysaccharide (LPS) was then treated for 6 hours. After centrifugation, the supernatant was dispensed into a TNF-α ELISA Kit (BD 555212) and absorbance was measured at 450 nm with an absorbance analyzer ELISA reader.

LPS로 유도된 염증반응에서 세포의 염증 지표물질인 사이토카인(Cytokine) 중 대표적인 TNF-α의 억제 정도를 측정하였다. LPS로 유도된 염증반응에서 분비되는 사이토카인 TNF-α의 양을 측정하여 이 값을 100으로 하였을 때 추출물 시료 처리군에서 분비되는 TNF-α의 양을 %로 환산하여 나타내었다. 또한, 추출물이 LPS로 유도된 TNF-α 생성을 감소시킨 것인지, 추출물의 세포 독성으로 인해 cell population 저하를 유발한 것인지 확인하기 위해 추출물 시료의 세포 독성과 비교하였다. In the inflammatory response induced by LPS, the degree of inhibition of TNF-α, a typical cytokine, was measured. The amount of TNF- [alpha] secreted by the LPS-induced inflammatory reaction was measured and expressed as the percentage of TNF- [alpha] secreted in the extract-treated group when this value was taken as 100. The cytotoxicity of extracts was compared with that of extracts to determine whether the extract reduced TNF-α production induced by LPS or caused cell population deterioration due to cytotoxicity of the extract.

그 결과, 각 추출물을 100 ug/ml의 농도로 세포에 처리하였을 때 세포의 생존율이 95 % 이상인 것으로 보아 산수유 추출물이 세포의 생존에는 영향을 미치지 않으면서 TNF-α를 억제하여 항염 효과를 발휘하는 것을 알 수 있었다(도 3).As a result, when the extracts were treated with cells at a concentration of 100 ug / ml, the survival rate of the cells was more than 95%, indicating that the extract of Cornus nipponensis did not affect the cell survival and inhibited TNF- (Fig. 3).

실험예 5. 산수유 추출물의 항염 활성 - NO(nitric oxide) 억제Experimental Example 5. Anti-inflammatory activity of oxalic acid extract-NO (nitric oxide) inhibition

RAW 264.7 세포주를 사용하여 10 %(v/v) FBS, 100 units/ml 페니실린, 100 ug/ml 스트렙토마이신을 포함하는 DMEM에 5×104 cells/well의 밀도로 96 웰 플레이트에 200 ul씩 분주하여 6 시간 동안 37 ℃, 5% CO2 배양기에서 배양하였다. 이후, LPS를 첨가한 추출물 시료를 각기 첨가량을 달리하여 첨가한 다음 16 시간 동안 배양하였다. Using a RAW 264.7 cell line, 200 μl aliquots were added to DMEM containing 10% (v / v) FBS, 100 units / ml penicillin and 100 ug / ml streptomycin at a density of 5 × 10 4 cells / And cultured in a 5% CO 2 incubator at 37 ° C for 6 hours. Then, LPS-added extract samples were added at different doses and cultured for 16 hours.

NO 분석을 위해 세포배양시 생성된 nitrate의 양을 측정하였다. 세포배양 상등액 150 ㎕를 취하여 원심분리한 후 상층액 100 ㎕와 Griess 시약 100 ㎕를 5 분간 반응시킨 다음, ELISA reader를 사용하여 540 nm에서 흡광도를 측정하였다. 이때, 표준품 NaNO2를 기준으로 최종적으로 생산된 NO의 상대적인 양을 비교하여 처리별 NO 억제 활성을 구하고 항염증 활성의 지표로 삼았다. 염증반응이 유도되면 NO 생성이 유도되는데 이를 nitrite에 대한 nitrate로 환원된 후의 안정된 형태를 greiss reagent로 측정한 것이다. LPS만 첨가한 군에서 생성된 NO의 양을 100 %로 하여 시료가 첨가된 것을 %로 환산하여 평가하였다. For NO analysis, the amount of nitrate produced during cell culture was measured. 150 μl of the cell culture supernatant was centrifuged, and 100 μl of the supernatant was reacted with 100 μl of Griess reagent for 5 minutes, and the absorbance was measured at 540 nm using an ELISA reader. At this time, the NO inhibitory activity of each treatment was compared with the relative amount of NO produced finally based on the standard NaNO 2 , and the activity was determined as an index of anti-inflammatory activity. When the inflammatory reaction is induced, NO production is induced, which is measured by the greiss reagent after stabilizing nitrate to nitrate. The amount of NO produced in the group to which LPS alone was added was regarded as 100%, and the addition of the sample was evaluated in terms of%.

그 결과, LPS는 염증반응을 유도한 대조군이므로 NO 억제 효과가 없고, LPS를 처리하지 않은 normal cell은 염증반응이 유도되지 않았으므로 NO 억제 효과가 100 %에 가까웠다. 각각의 추출물 시료의 NO 억제 효과는 50ug-200ug으로 농도가 높아질수록 높아짐을 알 수 있었다. MeOH 추출물 200 ug/ml 처리시 NO 억제 효과가 약 32 %인 것으로 나타났다(도 4).As a result, LPS did not inhibit NO because it was a control group that induced inflammation reaction, and normal cells without LPS treatment showed almost 100% NO inhibition effect because inflammation reaction was not induced. The NO inhibitory effect of each extract sample was increased to 50 ug-200 ug as the concentration increased. Treatment with 200 ug / ml of MeOH extract showed about 32% inhibition of NO (FIG. 4).

이상, 본 발명내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.
Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (10)

(1) 산수유(Cornus officinalis) 꽃을 세척하고 건조시키는 단계;
(2) 상기 건조된 산수유 꽃을 추출용매에 침지시켜 5 내지 100 ℃의 온도에서 12 내지 36시간 동안 추출하여 산수유 꽃 추출물을 제조하는 단계; 및
(3) 상기 제조된 산수유 꽃 추출물을 여과 및 농축시키는 단계에 따라 제조된 산수유 꽃 추출물을 유효성분으로 함유하며, 스타필로코커스 에피더미디스(Staphylococcus epidermidis) 균주의 생장을 억제하는 것을 특징으로 하는 항균 또는 항염 조성물.
(1) washing and drying Cornus officinalis flowers;
(2) a step of preparing the dried extract of corn oil by immersing the dried corn oil in an extraction solvent and extracting the corn oil at a temperature of 5 to 100 ° C for 12 to 36 hours; And
(3) an antimicrobial agent which contains the extract of a fermented soybean oil flower produced according to the step of filtrating and concentrating the above-prepared corn oil floral extract as an active ingredient and inhibits the growth of a Staphylococcus epidermidis strain Or anti-inflammatory composition.
삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete
KR1020130128604A 2013-10-28 2013-10-28 Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect Expired - Fee Related KR101575722B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020130128604A KR101575722B1 (en) 2013-10-28 2013-10-28 Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020130128604A KR101575722B1 (en) 2013-10-28 2013-10-28 Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect

Publications (2)

Publication Number Publication Date
KR20150048478A KR20150048478A (en) 2015-05-07
KR101575722B1 true KR101575722B1 (en) 2015-12-09

Family

ID=53386967

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020130128604A Expired - Fee Related KR101575722B1 (en) 2013-10-28 2013-10-28 Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect

Country Status (1)

Country Link
KR (1) KR101575722B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170130865A (en) 2016-05-19 2017-11-29 유한킴벌리 주식회사 Composition for anti-inflammatory or moisturizing on skin comprising plant extract
KR102766536B1 (en) 2025-01-02 2025-02-13 주식회사 라비오 Cosmetic Composition for Skin Whitening or Soothing Containing Fermented Cornus officinalis Extract Using Microbial Strains

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11665281B2 (en) * 2020-02-27 2023-05-30 Byung Kwan Jung Call recommendation system and call recommendation method based on artificial intelligence
KR20250080381A (en) * 2023-11-28 2025-06-05 주식회사 엑티브온 Composition containing fructan for moisturizing skin and improving skin microbiome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170130865A (en) 2016-05-19 2017-11-29 유한킴벌리 주식회사 Composition for anti-inflammatory or moisturizing on skin comprising plant extract
KR102766536B1 (en) 2025-01-02 2025-02-13 주식회사 라비오 Cosmetic Composition for Skin Whitening or Soothing Containing Fermented Cornus officinalis Extract Using Microbial Strains

Also Published As

Publication number Publication date
KR20150048478A (en) 2015-05-07

Similar Documents

Publication Publication Date Title
KR102171133B1 (en) Skin external composition comprising centella asiatica extract and papaver rhoeas extract
KR101064904B1 (en) Cosmetic composition for improving acne comprising a natural extract
KR101182209B1 (en) Antimicrobial Composition Containing Birch Extract Essential Oil
CN107213096A (en) A kind of plant type suncream and preparation method thereof
KR20200134929A (en) Cosmetic composition containing complex medicinal herbs extract for skin whitening and anti-wrinkle effect and manufacturing method thereof
KR102180666B1 (en) Cosmetic Composition for Skin Care Containing Fermented Extracts of Applemint, Citron and Sparassis Crispa
KR101332215B1 (en) Cosmetic composition containing fermentated complex of extracts with cryptomeria japonica and nelumbo nucifera for acne improvement and enhancing immune system
KR20150048478A (en) Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect
CN107898681A (en) A kind of Novel acne treatment naturally extracts composition, acne eliminating cream and preparation method thereof
KR102443283B1 (en) Cosmetic composition with excellent skin barrier using skin microbiome
KR20120009554A (en) Cosmetic composition containing herbal extracts having antioxidant and anti-allergic effects
KR100513659B1 (en) Cosmetic Composition for Improving Atopic Dermatitis Containing Extracts from Plants as Active Ingredient
KR20100134323A (en) Cosmetic composition for sebum suppression and acne improvement
KR102300581B1 (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR101877478B1 (en) Cosmetic composition for improving acne
KR101343133B1 (en) Soap composition containing rice bran and oriental medical resources and manufacturing method of the soap using the same
KR102453167B1 (en) Cosmetic composition for improving skin containing phyto-ceramide
KR101363028B1 (en) A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb
KR20060106554A (en) Baby swimming and / or rhubarb extract-containing cosmetic composition for improving atopic skin
KR101479550B1 (en) Cosmetics composition containing germinated Phaseolus radiatus, germinated Phaseolus angularis and extracts of Sophora flavescens
JP5972732B2 (en) Antibacterial agent and external preparation for skin
KR20230065023A (en) Cosmetic composition for skin improvement comprising natural products from Jeju
KR20230080174A (en) Composition for anti-oxidation, anti-inflammation, and acne comprising extracts unripe fruit derived from Poncirus trifoliata
KR102059620B1 (en) Cosmetic composition for allevation of acne with the extract of Lycopus lucidus or its fraction
KR102817974B1 (en) cosmetic composition for anti-oxidation, anti-inflammation, anti-bacteria, skin-suppression containing mixed plant ferment extracts

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20181126

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191203

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000